Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription

Articles published in
Anticancer Res
    May 2024
  1. CHEN CH, Chen YC, Chang YC, Hung CH, et al
    Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
    Anticancer Res. 2024;44:1963-1971.
    >> Share

  2. KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
    Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
    Anticancer Res. 2024;44:1947-1954.
    >> Share

  3. HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
    Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
    Anticancer Res. 2024;44:1837-1844.
    >> Share

  4. FUKUOKAYA W, Akazawa K, Kimura T
    Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2024;44:2117-2123.
    >> Share

  5. FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
    STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
    Anticancer Res. 2024;44:1925-1930.
    >> Share

    April 2024
  6. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
    Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
    Anticancer Res. 2024;44:1417-1423.
    >> Share

  7. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
    Anticancer Res. 2024;44:1675-1681.
    >> Share

    March 2024
  8. YU SH, Wang CY, Wang SS, Li JR, et al
    Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
    Anticancer Res. 2024;44:1299-1307.
    >> Share

  9. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
    Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Anticancer Res. 2024;44:1271-1279.
    >> Share

    February 2024
  10. ONER M, Lin E, Chiu KY, Chen MC, et al
    p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
    Anticancer Res. 2024;44:543-553.
    >> Share

    December 2023
  11. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:5689-5698.
    >> Share

    November 2023
  12. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
    Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Anticancer Res. 2023;43:5041-5050.
    >> Share

    October 2023
  13. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    >> Share

    September 2023
  14. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Anticancer Res. 2023;43:4055-4060.
    >> Share

  15. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    >> Share

    August 2023
  16. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    >> Share

  17. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    >> Share

    May 2023
  18. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    >> Share

    April 2023
  19. YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
    Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:1725-1730.
    >> Share

  20. LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2023;43:1437-1448.
    >> Share

  21. LEE YH, Wu RC, Mai HC, Huang WL, et al
    The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
    Anticancer Res. 2023;43:1521-1531.
    >> Share

    March 2023
  22. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    >> Share

  23. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    >> Share

    January 2023
  24. HASHIMOTO M, Fujita K, Tomiyama E, Fujimoto S, et al
    Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:167-174.
    >> Share

  25. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
    Anticancer Res. 2023;43:269-274.
    >> Share

    December 2022
  26. KOIZUMI M, Sato S, Yoshihara M, Nakamura Y, et al
    Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer.
    Anticancer Res. 2022;42:5783-5794.
    >> Share

    November 2022
  27. ECKE TH, Scislowski M, Hassan N, Saura M, et al
    Luminophore Chemistry for Detection of Urinary Bladder Cancer - Comparison to Cytology and Urinary Rapid Tests (BTA stat((R)), NMP22((R)) BladderChek((R)) and UBC((R)) Rapid Test).
    Anticancer Res. 2022;42:5249-5256.
    >> Share

    September 2022
  28. RADES D, Kopelke S, Schild SE, Kjaer TW, et al
    Evaluation of Sleep Disturbances in Patients With Bladder Cancer Scheduled for Local or Loco-regional Radiochemotherapy.
    Anticancer Res. 2022;42:4511-4515.
    >> Share

    August 2022
  29. VASSILIOU V, Katsila T, Sodergren SC, Kardamakis D, et al
    Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications.
    Anticancer Res. 2022;42:3767-3778.
    >> Share

    July 2022
  30. INOUE S, Sassa N, Kawanishi H, Yuguchi Y, et al
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
    Anticancer Res. 2022;42:3627-3636.
    >> Share

  31. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    >> Share

  32. WALLACE B, Dekalo S, Kabha M, Mintz I, et al
    Can We Predict a Higher Risk of Urothelial Bladder Cancer With a Simple Blood Test?
    Anticancer Res. 2022;42:3569-3573.
    >> Share

    March 2022
  33. TOMISAKI I, Harada M, Minato A, Nagata Y, et al
    Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Anticancer Res. 2022;42:1629-1634.
    >> Share

  34. FURUBAYASHI N, Morokuma F, Tomoda T, Hori Y, et al
    Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Anticancer Res. 2022;42:1571-1577.
    >> Share

  35. SALKINI MW, Yang X, Hashmi FH, Kandzari SJ, et al
    First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules - A Case Report.
    Anticancer Res. 2022;42:1339-1344.
    >> Share

    February 2022
  36. KURASHINA R, Ando K, Inoue M, Izumi K, et al
    Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.
    Anticancer Res. 2022;42:1131-1136.
    >> Share

    January 2022
  37. KACZOROWSKI M, Matysiak J, Kielb P, Malkiewicz B, et al
    Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers.
    Anticancer Res. 2022;42:493-500.
    >> Share

    December 2021
  38. WONG BS, Wu WT, Su JH, Goan YG, et al
    Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells.
    Anticancer Res. 2021;41:6123-6133.
    >> Share

  39. OKUBO K, REssING N, Schulz WA, Hansen FK, et al
    The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
    Anticancer Res. 2021;41:5987-5996.
    >> Share

    November 2021
  40. YUMIOKA T, Honda M, Shimizu R, Teraoka S, et al
    Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
    Anticancer Res. 2021;41:5767-5773.
    >> Share

  41. PALACKA P, Slopovsky J, Obertova J, Chovanec M, et al
    Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Anticancer Res. 2021;41:5749-5759.
    >> Share

  42. FISCHER N, Ellinger J, Koeditz B, Heidenreich A, et al
    Predictors for Outcome and Complications Related to Urinary Diversion.
    Anticancer Res. 2021;41:5585-5591.
    >> Share

    October 2021
  43. PAN Y, Hong YC, Hsiao CH, Shih HJ, et al
    Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2021;41:4957-4968.
    >> Share

    August 2021
  44. FOSSUM CC, Xiong Y, Magliocco A, Daneshmand S, et al
    Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2021;41:3851-3857.
    >> Share

  45. MUKAE Y, Ito H, Miyata Y, Araki K, et al
    Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
    Anticancer Res. 2021;41:3815-3823.
    >> Share

  46. MASILAMANI AP, Fischer A, Schultze-Seemann S, Kuckuck I, et al
    Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer.
    Anticancer Res. 2021;41:3741-3746.
    >> Share

  47. MATSUNAGA W, Hamada K, Tagawa M, Morinaga T, et al
    Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector.
    Anticancer Res. 2021;41:3731-3740.
    >> Share

    June 2021
  48. OKUBO K, Isono M, Asano T, REssING N, et al
    Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Anticancer Res. 2021;41:2901-2912.
    >> Share

    May 2021
  49. XIAO H, Alisic H, Reiman BT, Deng Z, et al
    IL-39 Reduces Proliferation and Promotes Apoptosis of Bladder Cancer by Altering the Activity of Cyclin E and Fas.
    Anticancer Res. 2021;41:2239-2245.
    >> Share

    December 2020
  50. ADELMANN TG, Camerota TC, Ceausu AR, Cimpean AM, et al
    Chloride Intracellular Channel Protein 1 (CLIC1) Iotas Over-expressed in Muscle Invasive Urinary Bladder Cancer.
    Anticancer Res. 2020;40:6879-6884.
    >> Share

    November 2020
  51. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Anticancer Res. 2020;40:6093-6099.
    >> Share

  52. SUN YU, Nishino H, Sugisawa N, Yamamoto J, et al
    Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
    Anticancer Res. 2020;40:6083-6091.
    >> Share

    October 2020
  53. MAJEWSKI W, Nieckula J, Dworzecki T, Miszczyk L, et al
    Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer - A Single-institution Experience.
    Anticancer Res. 2020;40:5861-5868.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016